SR&ED vs IRAP, and should I apply for grants or pitch investors first?

These are really one question, because the answer to the first determines the answer to the second.

SR&ED and IRAP are not alternatives. They stack.

Founders often treat this as a choice. It isn't. SR&ED is a tax credit refunding up to roughly 35% of eligible R&D spending for Canadian-controlled private corporations, claimable with no revenue. IRAP is a contribution programme reimbursing a share of technical salaries on an approved project. You can hold both, and most R&D-heavy Canadian companies should.

If you are asking which to start with, the practical answer is usually IRAP, for a reason that has nothing to do with the money: the application puts an Industrial Technology Advisor in the room with you. An ITA has seen a great many companies at your stage and knows the regional funding landscape in a way no public list captures. Founders regularly report that the advisor was worth more than the contribution.

SR&ED, meanwhile, rewards good record-keeping more than good applications. Start tracking eligible work now, in a form your accountant can use later, and the claim mostly writes itself.

The trap inside both of them

Say the timing out loud and the problem becomes obvious. SR&ED repays last year. IRAP repays last quarter. Mitacs wants a cheque up front. The reimbursement model means you need cash before the free cash shows up.

That gap — between the spending and the reimbursing — is not a detail. It is the first serious cash-flow challenge most founders meet, and it is consistently longer and deeper than planned for.

Which reframes the sequencing question

It isn't "grants or investors." It is: how much do I need in order to afford the money I've been awarded?

That is an unromantic sentence and a useful one. It turns a vague ordering problem into a number.

Start the non-dilutive paperwork early regardless, for a reason beyond the cash. Applications cost you time rather than equity, and a founder who has already been diligenced by IRAP walks into an investor meeting with an external party's homework on the table. Investors read "we have been approved for X" as a signal that somebody with no upside checked the claims.

What this means in practice

• Track SR&ED-eligible work from today, whether or not you claim this year.
• Approach IRAP for the advisor as much as the contribution.
• Size your first raise to cover the gap, not just the runway — they are different numbers.
• Treat every approval as evidence for the next conversation, non-dilutive or otherwise.